Granted Patent
B2
US 12,350,378 · App. 17/851,451 · Granted Jul 8, 2025
Extended release pharmaceutical formulation and methods of treatment
Inventors:
Paul William Glue (Dunedin, NZ); Natalie June Medlicott (Dunedin, NZ); Peter William Surman (Auckland, NZ)
Assignee:
DOUGLAS PHARMACETICALS LTD
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides an oral extended release formulation for the treatment of treatment-resistant depression, treatment-resistant anxiety, and phobia.
Claims (35)
1. A solid, oral, extended release pharmaceutical tablet comprising:
a core comprising:
i) a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof;
ii) at least one high molecular weight polyethylene oxide (PEO) that is cured, wherein said high molecular weight PEO has an approximate molecular weight of from about 2 million to about 7 million, based upon rheological measurements, and is present in an amount of at least about 30% (by weight) of the core,
wherein said tablet is crush resistant and has a breaking strength of at least about 200 N; and wherein said tablet comprises active agent at a concentration of at least about 12% by weight.
2. The tablet of claim 1 wherein the molecular weight of said high molecular weight PEO is selected from the group consisting of at least about 4,000,000; at least about 5,000,000; at least about 6,000,000; and at least about 7,000,000.
3. The tablet of claim 1 wherein said high molecular weight PEO comprises at least about 50% (by weight) of said core.
4. The tablet of claim 1 wherein the dosage amount of active agent is selected from the group consisting of about 30 mg, about 60 mg, about 120 mg, about 180 mg, and about 240 mg.
5. The tablet of claim 1 wherein the tablet is cured at a temperature of about 70° C. to about 75° C.
6. The tablet of claim 1 wherein the tablet is suitable for once weekly, twice weekly, three times weekly, once daily or twice-daily administration to a subject.
7. The tablet of claim 1 wherein the tablet has no or minimal dissociative side effects upon administration to a patient.
8. The tablet of claim 1 wherein after administration to a patient suffering from treatment-resistant depression or anxiety or phobia, the symptoms of said treatment-resistant depression or said anxiety or said phobia in said patient are measurably alleviated within about 1-3 or about 2 hours of oral administration of said ketamine to said patient.
9. The tablet of claim 1 wherein a single oral administration to a patient suffering from treatment-resistant depression or anxiety or phobia of said ketamine in doses between 30-180 mg is sufficient to alleviate the effects of said depression or said anxiety or said phobia for 3-7 days in said patient.
10. The tablet of claim 1 wherein the active agent is ketamine.
11. The tablet of claim 1 wherein said tablet provides a pharmacokinetic parameter of a ketamine C max between about 12 and about 42 ng/mL after administration of a single tablet to a patient.
12. The tablet of claim 1 wherein said tablet provides a pharmacokinetic parameter of a ketamine AUC 0-inf between about 79 and about 385 ngh/mL after administration of a single tablet to a patient.
13. The tablet of claim 1 wherein said tablet provides a pharmacokinetic parameter of a norketamine C max between about 7 4 and about 315 ng/mL after administration of a single tablet to a patient.
14. The tablet of claim 1 wherein said tablet provides a pharmacokinetic parameter of a norketamine AUC 0-inf between about 872 and about 4079 ngh/mL after administration of a single tablet to a patient.
15. A solid, oral, extended release pharmaceutical tablet comprising:
a core comprising:
i. a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof;
ii. at least one high molecular weight polyethylene oxide (PEO) that is cured, wherein said high molecular weight PEO has an approximate molecular weight of from about 2 million to about 7 million, based upon rheological measurements, and is present in an amount of at least 30% by weight of the core,
wherein said tablet is crush resistant and has a breaking strength of at least 200 N; wherein said tablet comprises active agent at a concentration of at least about 12% by weight, and wherein the tablet is cured at a temperature of about 70° C. to about 75° C.
16. A process of preparing a solid, oral, extended release pharmaceutical tablet comprising the steps of:
a) combining:
i. at least one high molecular weight polyethylene oxide (PEO), wherein said high molecular weight PEO has an approximate molecular weight of from about 2 million to about 7 million, based upon rheological measurements; and
ii. an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof, to form a composition;
b) shaping the composition to form a tablet; and
c) curing said tablet at a curing temperature of about 68° C. to about 80° C. for a time period of at least about 10 minutes,
wherein said tablet comprises active agent at a concentration of at least about 12% by weight.
17. A solid, oral, extended release pharmaceutical tablet obtained by a process according to claim 16 .
18. The tablet of claim 1 wherein said tablet comprises active agent at a concentration of at least about 12% to about 20% by weight.
19. The tablet of claim 15 wherein said tablet comprises active agent at a concentration of at least about 12% to about 20% by weight.
20. The process of claim 16 wherein said tablet comprises active agent at a concentration of at least about 12% to about 20% by weight.
21. A solid, oral, extended release pharmaceutical tablet obtained by a process according to claim 20 .
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 30, 2025
From: GLUE, PAUL WILLIAM; MEDLICOTT, NATALIE JUNE
To: UNIVERSITY OF OTAGO
Reel/Frame 071269/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 30, 2025
From: UNIVERSITY OF OTAGO
To: OTAGO INNOVATION LIMITED
Reel/Frame 071269/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 30, 2025
From: OTAGO INNOVATION LIMITED
To: DOUGLAS PHARMACEUTICALS LTD
Reel/Frame 071269/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 30, 2025
From: SURMAN, PETER WILLIAM
To: DOUGLAS PHARMACEUTICALS LTD
Reel/Frame 071269/0569 →
Continuity (4)
Continuation
16754389
Provisional Application
62695966
· Jul 10, 2018
References Cited (247)
US 6194000B1
· Smith
· 2001
[cited by applicant]
US 6280770B1
· Pather et al.
· 2001
[cited by applicant]
US 6692771B2
· Pather et al.
· 2004
[cited by applicant]
US 6855735B2
· Friedman
· 2005
[cited by applicant]
US 7776314B2
· Bartholomaus et al.
· 2010
[cited by applicant]
US 8114383B2
· Bartholomaus et al.
· 2012
[cited by applicant]
US 8137711B2
· Wolicki
· 2012
[cited by applicant]
US 8309060B2
· Bartholomaus et al.
· 2012
[cited by applicant]
US 9272037B2
· Singh
· 2016
[cited by applicant]
US 9533982B2
· Conn et al.
· 2017
[cited by applicant]
US 9650362B2
· Wainer et al.
· 2017
[cited by applicant]
US 9867830B2
· Wainer et al.
· 2018
[cited by applicant]
US 20050038062A1
· Burns et al.
· 2005
[cited by applicant]
US 20090004281A1
· Nghiem et al.
· 2009
[cited by applicant]
US 20090253728A1
· Meyerson et al.
· 2009
[cited by applicant]
US 20100029665A1
· Meyerson et al.
· 2010
[cited by applicant]
US 20130088135A1
· McCarthy et al.
· 2013
[cited by applicant]
US 20130217615A1
· Lasser et al.
· 2013
[cited by applicant]
US 20140020155A1
· Salama
· 2014
[cited by applicant]
US 20140112984A1
· Arkenau-Maric et al.
· 2014
[cited by applicant]
US 20150057306A1
· Fava et al.
· 2015
[cited by applicant]
US 20160106808A1
· Charney et al.
· 2016
[cited by applicant]
US 20170042878A1
· Fava et al.
· 2017
[cited by applicant]
US 20180098993A1
· Wainer et al.
· 2018
[cited by applicant]
WO 2009131794
· 2009
[cited by applicant]
WO 2013008135
· 2013
[cited by applicant]
WO 2013149102
· 2013
[cited by applicant]
WO 2014020155
· 2014
[cited by applicant]
WO 2014169272
· 2014
[cited by applicant]
WO 2015031410
· 2015
[cited by applicant]
WO 2016073653
· 2016
[cited by applicant]
WO 2018234568
· 2018
[cited by applicant]
WO 2019073408
· 2019
[cited by applicant]
Food and Drug Administration (FDA). FDA label SPRAVATO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf. Published 2019.
[cited by applicant]
Glue et al. (2020) “Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study” Ther Adv Vaccines 10:1-6 doi:10.1177/2045125320922474.
[cited by applicant]
Kryst et al. (2020) “Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials” Pharmacol Reports (0123456789) doi:10.1007/s43440-020-00…
[cited by applicant]
Peyrovian et al. (2020) “Registered clinical trials investigating ketamine for psychiatric disorders” J Psychiatr Res 127:1-12 doi:10.1016/j.jpsychires.2020.03.020.
[cited by applicant]
Singh et al. (2016) “A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression” Am J Psychiatry 173(8):816-826 doi:10.1176/appi.ajp.2016…
[cited by applicant]
Adhvaryu et al. (1986) “Genetoxic effects of ketamine on CHO cells” Arch Toxicology 59:124-125.
[cited by applicant]
Amorsa Therapeutics Inc (2014) “Developing a novel treatment for refractory cancer pain” Cancer Cluster Showcase Bio 2014 website www.amorsatx.com.
[cited by applicant]
Anderson et al. (2008) “Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychpharmacology guidelines” A Journal of Psychopharmacology 22(4…
[cited by applicant]
Amin et al. (2014) “Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain” J Pain Palliat Care Pharmacother 28(3): 233-242.
[cited by applicant]
Baker et al. (2016) “Ketamine-induced apoptosis in normal human urothelial cells: a direct, N-methyl-d-aspartate receptor-independent pathway characterized by mitochondrial stress” Am J Pathol 186(5): 1267-1277.
[cited by applicant]
Barkan et al. (2014)“A double blind, randomised, placebo controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair” Emergency Medicine Journal 31(8) 649-653.
[cited by applicant]
Bartova (2017) “Robust antidepressant effect following alternating intravenous racemic ketamine and electroconvulsive therapy in treatment-resistant depression: a case report” Journal of ECT 00(00).
[cited by applicant]
Berman et al. (2000) “Antidepressant effects of ketamine in depressed patients” Biol Psychiatry 47:351-354.
[cited by applicant]
Beaudoin et al. (2014) “Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial” Acad Emerg Med …
[cited by applicant]
Boulieu (1998) “HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent” Clinical Chemistry 44(3): 560-564.
[cited by applicant]
Bredlau et al. (2013) “Oral ketamine for children with chronic pain: a pilot phase 1 study” J Pediatr 163(1): 194-200 e191.
[cited by applicant]
Bremner et al. (1998) “Measurement of dissociative states with the clinical-administered dissociative states scale (CADSS)” Journal of Traumatic Stress 11(1).
[cited by applicant]
Brooks (2016) “Repeated ketamine may sustain antidepressant effect” American Journal of Psychiatry.
[cited by applicant]
Brown et al. (1996) “Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders” American Journal of Psychiatry 153(10):1293-1300.
[cited by applicant]
Brunette et al. (2011) “Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures” Pediatric Anesthetics 21(6):653-662.
[cited by applicant]
Busner (2007) “The clinical global impressions scale: applying a research tool in clinical practice” Psychiatry 4:28-37.
[cited by applicant]
Caddy et al. (2014) “Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions and a systematic review and meta-analysis of efficacy” Therapeutic Advances in Psychopharmacology 4(2):75-99.
[cited by applicant]
Cani et al. (2015) “Endocannabinoids—at the crossroads between the gut microbiota and host metabolism” Nature Reviews Endocrinology 12(3): 133-143.
[cited by applicant]
Carliss et al. (2007) “Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain” Science Direct Neuro Toxicology 28: 813-818.
[cited by applicant]
Carreno et al. (2016) “Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine” Mol Psychiatry 21(9):1298-1308.
[cited by applicant]
Chang et al. (2004) “Mechanisms involved in the antiplatelet activity of ketamine in human platelets” Journal of Biomed Science 11:764-772.
[cited by applicant]
Chen et al. (1998) “Neuroprotective concentrations of the N-methyl D-aspartate open channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze le…
[cited by applicant]
Chen et al. (2012) “Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression” Expert Opinion Drug Metabolism Toxicology 6(3):273-281.
[cited by applicant]
Chong et al. (2009) “Development of sublingual/oral formulation of ketamine for use in neuropathic pain” Clinical Drug Investigation 29(5):317-324.
[cited by applicant]
Clements, Grant (1981) “Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans” Journal of Pharmaceutical Sciences 71(5):539-542.
[cited by applicant]
Conway et al. (2017) “Toward an evidence-based, operational definition of treatment-resistant depression, when enough is enough” JAMA Psychiatry 74(1): 9-10.
[cited by applicant]
Correll et al. (2006) “Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions” Pain Medicine 7(1):92-95.
[cited by applicant]
Cox (2019) “Ketamine: Can it really be an antidepressant?” The Guardian, https://theguardian.com/science2019/mar23/ketamine-can-it-really-be-an-antidepressant (pp. 1-7).
[cited by applicant]
Coyle (2013) “Nitric oxide and symptom reduction in Schizophrenia” Jama Psychiatry 70(7):664-5.
[cited by applicant]
Critical review of ketamine 34th ECDD 2006/4.3, Sep. 2002.
[cited by applicant]
Cvrcek (2008) “Side effects of ketamine in the long-term treatment of neuropathic pain” Pain Medicine 9(2):253-257.
[cited by applicant]
Daly et al. (2018) “Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial” JAMA psychiatry 75(2):139-148.
[cited by applicant]
Daly et al. (2019) “Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial” JAMA Psychiatry 76:893-903.
[cited by applicant]
Declaration of Paul William Glue under 37 C.F.R. 1.132 submitted in U.S. Appl. No. 16/362,848 dated Jul. 6, 2020.
[cited by applicant]
Declaration of Zhen shi under 37 C.F.R. 1.132 submitted in U.S. Appl. No. 16/362,848 dated Jul. 6, 2020.
[cited by applicant]
De Gioannis et al. (2014) “Oral ketamine augmentation for chronic suicididality in treatment-resistant depression” Aust N Z J Psychiatry 48(7): 686.
[cited by applicant]
Domino et al. (1982) “Plasma levels of ketamine and two of its metabolities in surgical patients using a gas chromatographic mass fragmentographic assay” Anesthesia and Analgesia 61:87-92.
[cited by applicant]
Downey et al. (2016) “Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate” European Neuropsychopharmacology 26(6):994-1003.
[cited by applicant]
Duman et al. (2012) “Signaling pathways underlying the rapid antidepressant actions of ketamine” Neuropharmacology 62(1):35-41.
[cited by applicant]
Ebert et al. (1997) “Norketamine: the main metabolite of ketamine is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord” European Journal of Pharmacology 20(333)(1):99-104.
[cited by applicant]
Emarson (1999) “Clinical experience with oral ketamine” Journal of Pain and Symptom Management 17(5).
[cited by applicant]
Erdil et al. (2015) “Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy” J Anesth 29(2): 180-185.
[cited by applicant]
Fanta et al. (2015) “Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing” Eur J Clin Pharmacol 71(4):441-7.
[cited by applicant]
Feder (2014) “Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder” JAMA Psychiatry 71(6):681-688.
[cited by applicant]
Fekadu et al. (2009) “A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method” Journal of Clinical Psychiatry 70(2):177-184.
[cited by applicant]
Fields et al. (2015) “Pill Properties that Cause Dysphagia and Treatment Failure” Current therapeutic research 77: 79-82.
[cited by applicant]
Fox et al. (2012) “Developmental origins of adult diseases and neurotoxicity: epidemiological and experimental studies” Neurotoxicology 33(4):810-816.
[cited by applicant]
Fredriksson et al. (2004) “Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD” Neurotoxicity Research 6(6):435-456.
[cited by applicant]
Furuhashi-Yonaha (2002) “Short and long-term efficacy of oral ketamine in eight chronic pain patients” Canadian Journal of Anesthesia 886-887.
[cited by applicant]
Ghasemi et al. (2014) “Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder” Psychiatry Res 215(2): 355-361.
[cited by applicant]
Gills (1995) “Normative values for the beck anxiety inventory, fear questionnaire, Penn State worry questionnaire, and social phobia and anxiety inventory” Psychological Assessment 7(4):450-455.
[cited by applicant]
Glue et al. (2010) “Meta-analysis of relapse prevention antidepressant trials in depressive disorders” Aust NZ J Psychiatry 44:697-705.
[cited by applicant]
Glue et al. (2017) “Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders” Journal of Psychopharmacology 31(10):1302-1305.
[cited by applicant]
Glue et al. (2018) “Safety and efficacy of maintenance ketamine treatments in patients with treatment-refractory generalised anxiety and social anxiety disorders” Journal of Psychopharmacology 32(6) https://doi.org/10.1…
[cited by applicant]
Glue et al. (2020) “Ascending-dose study of controlled-release ketamine tablets in healthy volunteers, pharmacokinetics, pharmacodynamics, safety, and tolerability” The Journal of Clinical Pharmacology, 60(6): 751-757.
[cited by applicant]
Gough et al. (1995) “Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party” Drug Information Journal 29:1039-1048.
[cited by applicant]
Grande et al. (2016) “(417) Oral ketamine for chronic pain: a 32-subject placebo-controlled trial in patients on chronic opioids” The Journal of Pain 17(4): S78-S79.
[cited by applicant]
Grant (1981) “Pharmacokinetics and analgesic effects of I.M. and oral ketamine” British Journal of Anesthesia 53(8):805-810.
[cited by applicant]
Haile et al. (2014) “Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression” International Journal of Neuropsychopharmacology 17(2):331-336.
[cited by applicant]
Hallak et al. (2013) “Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial” JAMA Psychiatry 70(7):668-676.
[cited by applicant]
Hamilton (1957) “The assessment of anxiety states by rating” Department of Psychiatry, University of Leeds p. 50-55.
[cited by applicant]
Harraz et al. (2016) “Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation” Molecular Psychiatry 21(3):313-9.
[cited by applicant]
Hartberg et al. (2018) “Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study” Psychopharmacology (Berl) 235(2):393-398.
[cited by applicant]
Hasan et al. (2021) “Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects” Anesthesiology 135:326-339.
[cited by applicant]
Hocking, Cousins (2003) “Ketamine in chronic pain management: an evidence-based review” Anesthesia and Analgesia 97(6): 1730-1739.
[cited by applicant]
Horacek (2012) “The influence of clonidine on oral ketaminemidazolam premedication in intellectually disabled patients indicated for . . . ” Neuro Endocrinology Letters 33(4):380-384.
[cited by applicant]
Hu et al. (2016) “Single IV ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study” Psychol Med 46(3): 623-635.
[cited by applicant]
Huang et al. (2016) “Ketamine affects the neurogenesis of the hippocampal dentate gyrus in 7 day old rats” Neurotox Rex 30:185-198.
[cited by applicant]
Humphrey et al. (2012) “The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score” European Association of Urology 61:271-279.
[cited by applicant]
International Search Report dated Sep. 8, 2020 for PCT/IB2020/051909.
[cited by applicant]
International Search Report dated Dec. 27, 2021 for PCT/IB2021/058647.
[cited by applicant]
International Search Report dated Jan. 28, 2019 for PCT/IB2018/057851.
[cited by applicant]
Ionescu et al. (2014) “Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine” J Clin Psychiatry 75(9): e932-938.
[cited by applicant]
Irwin et al. (2010) “Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care” Journal of Palliative Medicine 13(7):903-908.
[cited by applicant]
Irwin (2013) “Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial” Journal of Palliative Medicine 16(8):958-965.
[cited by applicant]
Jafarina et al. (2016) “efficacy and safety or oral ketamine versus diclofanec to alleviate mild to moderate depression in chronic pain patients: a double blind, randomized, controlled trial” J affect discord 204:1-8.
[cited by applicant]
Janssen (2000), “Ketamine dreams and realities” Florida, USA, Multidisciplinary Association for Psychedelic Studies (MAPS).
[cited by applicant]
Janssen (2015) “A study of evaluate the efficacy, safety, and tolerability of intranasal eskatimine plus an oral antidepressant in elderly participants with treatment-resistant depression” Transform 3.
[cited by applicant]
Janssen (2015) “Ketamine plus lithium in treatment-resistant depression” Study.
[cited by applicant]
Janssen (2015) “Ketamine trial for the treatment of depression”.
[cited by applicant]
Janssen Research and Development (2014) “A double-blind, doubly-randomized, placebo-controlled study of intranasal esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment-resistant depres…
[cited by applicant]
Janssen Research and Development (2015) “A study of ketamine in patients with treatment-resistant depression”.
[cited by applicant]
Janssen Research and Development (2015) “A study to evaluate the efficacy, safety, and tolerability of flexible doses of intranasal esketamine plus an oral antidepressant in adult participants with treatment-resistant d…
[cited by applicant]
Jarventausta et al. (2013) “Effects of s-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study” J ECT 29(3): 158-16…
[cited by applicant]
Jennings et al. (2013) “Oral ketamine for sickle cell crisis pain refractory to opioids” J Pain Palliat Care Pharmacotherapy 27(2): 150-154.
[cited by applicant]
Jevtovice-Todorovic (2001) “A comparative evaluation of neurotoxic properties of ketamine and nitrous oxide” Brain Research 895:264-267.
[cited by applicant]
Kannan, Bhatnagar (2002) “Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients” Journal of Pain and Symptom Management 23(1):60-65.
[cited by applicant]
Katalinic et al. (2013) “Ketamine as a new treatment for depression: a review of its efficacy and adverse effects” Australian & New Zealand Journal of Psychiatry 47(8): 710-727.
[cited by applicant]
Kessler et al. (2011) The global burden of mental disorders: an update from the WHO world mental health (WMH) surveys Epidemiology and Psychiatric Sciences 18(1):23-33.
[cited by applicant]
Koksal (2015) “Analysis of genotoxic activity of ketamine and rocuronium bromide using the somatic mutation and recombination test in
[cited by applicant]
Kundra et al. (2013) “Oral ketamine and dexmedetomidine in adults' burns wound dressing—a randomized double blind cross over study” Burns 39(6):1150-1156.
[cited by applicant]
Lai et al. (2014) “Pilot dose-response trial of IV ketamine in treatment-resistant depression” World J Biol Psychiatry 15(7): 579-584.
[cited by applicant]
Lara et al. (2013) “Antidepressant, mood stabilizing and precognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression” International Journal of Neuropsychopharmacology 16(9): 2…
[cited by applicant]
Leffa et al. (2016) Anesthetic ketamine-induced DNA damage in different cell types in vivo Mol Neurobiol 53(8): 5575-581.
[cited by applicant]
Lenze et al. (2016): “Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial” World J Biol Psychiatry 17(3):230-238.
[cited by applicant]
Li et al. (2010) “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists” Science 329(5994):959-964.
[cited by applicant]
Li et al. (2016) “The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study” Hum Brain Mapp 37(3): 1080-1090.
[cited by applicant]
Locklear (2016) “Drug quickly quells suicidal thoughts” New Scientist p. 12.
[cited by applicant]
Loo et al. (2012) “Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial” J Affect Disord 142(1-3):233-240.
[cited by applicant]
Loo et al. (2016) “Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular, and subcutaneous routes for ketamine in depression” Acta Psychiatry Scand 134(1):48-56, doi 10, 111/acps. 12572, E…
[cited by applicant]
Lu et al. (2012) “Sedating pediatric dental patients by oral ketamine with alternating bi-lateral stimulation of eye movement desensitization and minimizing adverse reaction of ketamine by acupuncture and bi-digital o-r…
[cited by applicant]
Maggi et al. (2002) “Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (POs) for the controlled release of a water-soluble drug. Dimensionality study” Biomaterials 23:1113-…
[cited by applicant]
Malhi et al. (2009) “Clinical practice recommendations for depression” Acta Psychiatry Scand Supply 439:8-26.
[cited by applicant]
Manji, Mullard (2015) “Husseini Manji” Nat Rev Drug Discovery 14(11): 742-743.
[cited by applicant]
Marchetti et al. (2015) “Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5-year study of 51 patients” Eur J Pain 19(7): 984-993.
[cited by applicant]
Matthew et al. (2012) “Ketamine for treatment-resistant unipolar depression: current evidence” CNS Drugs 26(3): 189-204.
[cited by applicant]
McClintock et al. (2014) “Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy” J ECT 30(2): 165-176.
[cited by applicant]
McNulty (2012) “Compounded oral ketamine for severe depression, anxiety, pain in a hospice patient with end-stage chronic obstructive pulmonary disease, cardiopulmonary failure, and severe renal insufficiency: a case re…
[cited by applicant]
Melander et al. (2008) “A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants” Eur Neuropsychopharmacol 18:623-627.
[cited by applicant]
Meneguz et al. (1999) “Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo” Exp Toxic Pathol 51:393-396.
[cited by applicant]
Moaddel et al. (2015) “D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression” Psychopharmacology (Berl) 232(2): 399-409.
[cited by applicant]
Montgomery (1979) “A new depression scale designed to be sensitive to change” British Journal of Psychiatry 134:382-389.
[cited by applicant]
Moreira et al. (2013) “Combined oral midazolam-ketamine better than midazolam alone for sedation of young children: a randomized controlled trial” International Journal of Pediatric Dentistry 23(3):207-215.
[cited by applicant]
Motamed et al. (2012) “Midazolam-ketamine combination for moderate sedation in upper GI endoscopy” Journal of Pediatric Gastroenterology and Nutrition 54(3):422-426.
[cited by applicant]
Mucalo, Rathbone (2012) “Melt-extruded polyethylene oxide (PEO) rods as drug delivery vehicles: formulation, performance as controlled release devices and the influence of co-extruded excipients on drug release profiles…
[cited by applicant]
Mundt (2002) “The work and social adjustment scale: impairment in ME and depression study a simple measure of impairment in functioning” British Journal of Psychiatry 180:461-464.
[cited by applicant]
Murrough et al. (2013) “Rapid and longer-term antidepressant effects of repeated Ketamine infusions in treatment-resistant major depression” Biol Psychiatry 74(4):250-256.
[cited by applicant]
Murrough et al. (2015) “Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial” Psychol Med 45(16): 3571-3580.
[cited by applicant]
Nemeroff (2007) “Prevalence and management of treatment-resistant depression” J Clin Psychiatry 68(8):17-25.
[cited by applicant]
Newport et al. (2016) “Whither ketamine as an antidepressant: panacea or toxin” Depression and Anxiety 33(8): 685-688.
[cited by applicant]
Niesters et al. (2014) “Ketamine for chronic pain: risk and benefits” Br J Clin Pharmacology 77(2): 357-367.
[cited by applicant]
Noppers et al. (2011) “Effect of rifampicin on s-ketamine and s-norketamine plasma concentrations in healthy volunteers after intravenous s-ketamine administration” Anesthesiology 114(6): 1435-1445.
[cited by applicant]
Norambuena et al. (2013) “Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study” Journal of Pediatric Surgery 48(3):629-634.
[cited by applicant]
Norouzi et al. (2015) “Comparison of the effects of oral vs. peritonsillar inflitration of ketamine in pain reduction after tonsillectomy: a randomized clinical trial” M.E.J. Anesth 23(1):29-38.
[cited by applicant]
Novicki et al. (1985) “Inhibition of DNA synthesis by chemical carcinogens in cultures of initiated and normal proliferating rat hepatocytes” Cancer Research 45:337-344.
[cited by applicant]
Nunez et al. (2020) “An update on the efficacy and tolerability of oral ketamine for major depression: A systematic review and meta-analysis”, Psychopharmacology Bulletin 50(4):137-163.
[cited by applicant]
O'Hara et al. (2014), “A 2 year experience of nurse led conscious sedation in pediatric burns” Burns 40(1): 48-53.
[cited by applicant]
Olney, Price (1989) “Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs” Science 244: 1360-1362.
[cited by applicant]
Olney et al. (1991) “NMDA antagonist neurotoxicity: mechanism and prevention” Science 254: 1515-1518.
[cited by applicant]
Overall et al. (1984) “The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit” J Gerontol 39:187-193.
[cited by applicant]
Papadimitropoulou et al. (2017) “Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis” C…
[cited by applicant]
Paslakis et al. (2010) “Oral administration of the NMDA receptor antagonist s-ketamine as add-on therapy of depression: case studies” Pharmacopsychiatry 43(1):33-5.
[cited by applicant]
Paul et al. (2014) “(R-S)-ketamine metabolites (R-S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function” Anesthesiology 121: 149-159.
[cited by applicant]
Peltoiemi et al. (2012) “S-ketamine concentrations are greatly increased by grapefruit juice” European Journal of Clinical Pharmacology 68(6):979-986.
[cited by applicant]
Peltoiemi et al. (2012) “Rifampicin has a profound effect on the pharmacokinetics of oral s-ketamine and less on intravenous s-ketamine” Basic and Clinical Pharmacology & Toxicology 111: 325-332.
[cited by applicant]
Permoda-Osip et al. (2015) “Single ketamine infusion and neurocognitive performance in bipolar depression” Pharmacopsychiatry 48(2): 78-79.
[cited by applicant]
Posner (2008) “The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults” Am J Psychiatry 168(12):1266-77.
[cited by applicant]
Preskorn (2015) “Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent” J Psychiatry P…
[cited by applicant]
Purdue (2009) FDA Advisory Committee on Reformulated Oxycontin FDA.
[cited by applicant]
Rasmussen et al. (2013) “Serial infusions of low-dose ketamine for major depression” Journal of Psychopharmacology 27(5):444-450.
[cited by applicant]
Rasmussen et al. (2014) “A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy” Psychiatry Res 215(2): 362-365.
[cited by applicant]
Rao et al. (2016) “Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance” Anesthesiology 125(6): 1103-1112.
[cited by applicant]
Rodriguez et al. (2013) “Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept” Neuropsychopharmacology 38(12):2475-2483.
[cited by applicant]
Rofael et al. (2003) “Immunomodulation by cocaine and Ketamine in postnatal rats” Toxicology 188:101-114.
[cited by applicant]
Rolan (2016) “Report on preliminary results from study KET-009”.
[cited by applicant]
Rush et al. (2006) “Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a star'd report” American Journal of Psychiatry 163:1905-1917.
[cited by applicant]
Salvadore et al. (2013) “Ketamine as a fast acting antidepressant: current knowledge and open questions” CNS Neurosci Ther 19(6):428-436.
[cited by applicant]
Sanacora et al. (2014) “Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects” Mol Psychiatry 19(9): 978-985.
[cited by applicant]
Sanacora et al. (2015) “Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?” Neuropsychopharmacology 40(2):259-267.
[cited by applicant]
Schoevers et al. (2016) “Oral ketamine for the treatment of pain and treatment-resistant depression” The British Journal of Psychiatry 208(2):108-113.
[cited by applicant]
Shillinburg et al. (2017) “Treatment of severe mucositis pain with oral ketamine mouthwash” Support Care Cancer 25(7): 2215-2219.
[cited by applicant]
Shirawi et al. (2017) “Oral ketamine in treatment-resistant depression: a clinical effectiveness case series” J Clin Psychopharmacol 37(4): 464-467.
[cited by applicant]
Sigtermans et al. (2009) “Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1” Pain 145(3):304-311.
[cited by applicant]
Short et al. (2018) “Side-effects associated with ketamine use in depression: a systematic review” Lancet Psychiatry 5:65-78.
[cited by applicant]
Slikker et al. (2007) “Ketamine-induced neuronal cell death in the perinatal phesus monkey” Toxicology Sciences 98(1): 145-158.
[cited by applicant]
Smeyne et al. (2016) “Assessment of the effects of MPTP and paraquat on dopaminergic neurons and microglia in the substantia nigra pars compacta of C57BL/6 mice” PLoS One 11(10): e0164094.
[cited by applicant]
Smith (2000) “Confidence interval criteria for assessment of dose proportionality” Pharmaceutical Research 17(10):1278-1283.
[cited by applicant]
Sos et al. (2013), “Relationship of ketamine's antidepressant and psychomimetic effects in unipolar depression” Activitas Nervosa Superior Rediviva 34(4): 287-298.
[cited by applicant]
Starte et al. (2012) “Ketamine-associated corneal edema” Cornea 31(5)572-274.
[cited by applicant]
Suehs et al. (2008) “Texas Medication Algorithm Project Procedure” Manual Major Depressive Disorder Algorithms 1-68.
[cited by applicant]
Swiatek et al. (2016) “New use for an old drug: oral ketamine for treatment-resistant depression” BMJ Case Rep 2016.
[cited by applicant]
Teche et al. (2013) “Measurement methods of BDNF levels in major depression: a qualitative systematic review of clinical trials” Psychiatry Q 84(4): 485-497.
[cited by applicant]
The Dow Chemical Company (2014) Reasonable Upper Limit of the Amount of Sentry Polyox.
[cited by applicant]
Viberg et al. (2008) “Neonatal ketamine exposure results in changes in biochemical substrates of neuronal growth and synaptogenisis, and alters adult behavior irreversibly” Toxicology 249: 153-159.
[cited by applicant]
Wang et al. (2012) “Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder” J ECT 28(2):128-132.
[cited by applicant]
Wang et al. (2013) “Preclinical assessment of ketamine” CNS Neuroscience Therapy 19(6):448-453.
[cited by applicant]
Wang et al. (2013) Brain damages in ketamine addicts as revealed by magnetic resonance imaging Front Neuroanat 7:23.
[cited by applicant]
Weigand (2000) “Ketamine modulates the stimulated adhesion molecule expression on human neutrophils in vitro” Anesthesia & Analgesia 90:206-212.
[cited by applicant]
Wilson (2011) “Controlled release in oral drug delivery” Advances in Delivery Science and Technology 427 pages.
[cited by applicant]
Wolfson (2016) “The ketamine papers” Science, Therapy, and Transformation 448 pages.
[cited by applicant]
Xu et al. (2016) “Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis” International Journal of Neuropsychopharmacology 19(4):1-15.
[cited by applicant]
Yan (2014) “Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain” Journal of Neurosurgical Anesthesiology 26(2):155-160.
[cited by applicant]
Yanagihara et al. (2003) “Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers” Biopharmaceutics & drug disposition 24(1):37-43.
[cited by applicant]
Yang et al. (2015) “R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects” Translational Psychiatry 5:e632.
[cited by applicant]
Yoosefi et al. (2014) “Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study” J ECT 30(1): 15-21.
[cited by applicant]
Yuasa et al. (1992) “Influence of anesthetic regimes on intestinal absorption in rats” Pharmaceutical Research 10(6):884-888.
[cited by applicant]
Zanicotti et al. (2013) “Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer” Journal of Palliative Medicine 16(7):1-2.
[cited by applicant]
Zanos et al. (2016) “NMDAR inhibition-independent antidepressant actions of ketamine metabolites” Nature 533(7604):481-486.
[cited by applicant]
Zarate (2017) “Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders” Molecular Psychiatry 22(3):324-327.
[cited by applicant]
Zhang et al. (2016) “Reactive oxygen species-mediated loss of phenotype of parvalbumin interneurons contributes to long term cognitive impairments after repeated neonatal ketamine exposures” Neurotox Res 30: 593-605.
[cited by applicant]
Zhao et al. (2012) “Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression” The British Pharmalogical Society 74(2): 304-314.
[cited by applicant]
Zhao et al. (2014) “Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring” Neurobiology of Disease 68:145-155.
[cited by applicant]
Zhao et al. (2017) “Self-assembled ZnO nanoparticle capsules for carrying and delivering isotretinoin to cancer cells” ACS Appl Mater Interfaces 9(22): 18474-18481.
[cited by applicant]
Zuroff et al. (2013) “Consortia-mediated bioprocessing of cellulose to ethanol with a symbiotic Clostridium phytofermentans/yeast co-culture” Biotechnology for Biofuels 6:59.
[cited by applicant]